WebApr 11, 2024 · Vaxxas raises $23 million for needle free drug-delivery technology. Vaxxas, the Brisbane-based company, developing a platform delivery technology initially developed in the University of Queensland (Brisbane, Australia) announced on 5 December 2024 that it had raised US$2 million to facilitate its clinical program including the development of its … WebAug 11, 2024 · GalNAc, N-acetylgalactosamine; PEG, polyethylene glycol; ... a key issue will be how the safety of different drug sequences using the same chemistry/delivery …
GalNAc-siRNA Conjugates: Leading the Way for Delivery …
WebMay 24, 2024 · Hello, I Really need some help. Posted about my SAB listing a few weeks ago about not showing up in search only when you entered the exact name. I pretty … WebAug 16, 2024 · A proprietary GalNAc delivery system with enhanced Endosome Escape and Dual-Targeting. GAITHERSBURG, Md. and SUZHOU, China, Aug. 16, 2024 /PRNewswire/ --Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, … hyperion synth
Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM ... - BioSpace
WebOur proprietary GalXC platform leverages a naturally occurring biologic process, ribonucleic acid interference, or RNAi, to create therapies that silence disease-causing genes. ... GalNAc, that is specifically … WebIntellectual Property. We have a robust and growing intellectual property estate covering our mRNAi GOLD™ platform, including all aspects of siRNA modification, delivery, … WebGalNAc-RNAi delivery platform for administration of RNAi therapeutics to the liver, Peptide docking vehicle (PDOV) platform for improved delivery and release of siRNAs into the hepatocytes in the liver; PLNP delivery platform for … hyperion talent agency